Shots:

• CEPI to provide $4.4M to Novavax & the University of Oxford for accelerating the development of vaccines against COVID-19. CEPI has invested up to $23.7M in R&D of COVID-19 vaccines
• Novavax is assessing multiple nanoparticle vaccine candidates to identify the best candidates for clinical studies. CEPI will provide the initial funding to Novavax for the initiation of P-I study- which is expected to be initiated in H1’20
• The company has developed the vaccine candidates using its recombinant protein nanoparticle technology to generate antigens derived from the coronavirus spike protein and is expected to utilize its Matrix-M adjuvant to enhance the immune response of vaccine candidates

Source 1- Source 2 ­to­ read full press release/ article | Ref: CEPI- GlobeNewswire | Image: CEPI